Retained Earnings (Accumulated Deficit) of CITIUS ONCOLOGY, INC. from 31 Dec 2021 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- The cumulative amount of the reporting entity's undistributed earnings or deficit.
- Summary
-
CITIUS ONCOLOGY, INC. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2021 to 31 Dec 2025.
- CITIUS ONCOLOGY, INC. Retained Earnings (Accumulated Deficit) for the quarter ending 31 Dec 2025 was $69,574,025, a 51% decline year-over-year.
- Source SEC data
- View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)
CITIUS ONCOLOGY, INC. Quarterly Retained Earnings (Accumulated Deficit) (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $69,574,025 | -$23,636,233 | -51% | 31 Dec 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q3 2025 | $64,039,956 | -$24,761,369 | -63% | 30 Sep 2025 | 10-Q | 13 Feb 2026 | 2026 | Q1 |
| Q2 2025 | $59,043,300 | -$56,003,183 | -1842% | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q3 |
| Q1 2025 | $53,673,344 | -$51,217,186 | -2085% | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q2 |
| Q4 2024 | $45,937,792 | -$43,950,063 | -2211% | 31 Dec 2024 | 10-Q | 14 Feb 2025 | 2025 | Q1 |
| Q3 2024 | $39,278,587 | -$21,148,747 | -117% | 30 Sep 2024 | 10-K | 23 Dec 2025 | 2025 | FY |
| Q2 2024 | $3,040,117 | -$3,037,907 | 30 Jun 2024 | 10-Q | 09 Aug 2024 | 2024 | Q2 | |
| Q1 2024 | $2,456,158 | -$2,653,502 | -1345% | 31 Mar 2024 | 10-Q | 20 May 2024 | 2024 | Q1 |
| Q4 2023 | $1,987,729 | -$2,332,995 | -676% | 31 Dec 2023 | 10-Q | 09 Aug 2024 | 2024 | Q2 |
| Q3 2023 | $18,129,840 | -$18,119,727 | -179173% | 30 Sep 2023 | 10-K | 27 Dec 2024 | 2024 | FY |
| Q2 2023 | $2,210* | 30 Jun 2023 | 10-Q | 16 Aug 2023 | 2023 | Q2 | ||
| Q1 2023 | $197,344 | 31 Mar 2023 | 10-Q | 15 May 2023 | 2023 | Q1 | ||
| Q4 2022 | $345,266 | +$355,379 | 31 Dec 2022 | 10-K | 16 Apr 2024 | 2023 | FY | |
| Q3 2022 | $10,113 | 30 Sep 2022 | 10-Q | 28 Nov 2022 | 2022 | Q3 | ||
| Q4 2021 | $10,113 | 31 Dec 2021 | 10-K | 17 Apr 2023 | 2022 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.